Estradiol Vaginal Ring vs. Oral Oxybutynin for Overactive Bladder

Both treatments were equally effective at diminishing urinary frequency.

Overactive bladder (urinary urgency and frequency with or without urge incontinence) affects as many as 40% of postmenopausal women. Behavior modification, pelvic floor exercises, and anticholinergic agents (e.g., oxybutynin chloride) are among first-line therapies; however, because side effects are common with such agents, topical estrogens are sometimes prescribed instead. In a manufacturer-funded, 12-week, randomized study, 59 postmenopausal women with urgency and frequency received either the ultralow-dose estradiol vaginal ring (Estring; 7.5 μg 17β-estradiol released daily) or oral oxybutynin (5 mg twice daily).

Women in both groups had similar decreases in number of voids during a 24-hour period (from a mean of 14.9 to 10.4 for the vag…

Reviewing Author

Robert W. Rebar, MD

Disclosures

Consultant/Advisory BoardMyovant Sciences, Inc.

Editorial BoardsEndoText; Clinical OB/GYN Alert

Leadership Positions in Professional SocietiesAmerican Society for Reproductive Medicine (Member, Ethics Committee)

Robert W. Rebar, MD

Disclosures

Consultant/Advisory BoardMyovant Sciences, Inc.

Editorial BoardsEndoText; Clinical OB/GYN Alert

Leadership Positions in Professional SocietiesAmerican Society for Reproductive Medicine (Member, Ethics Committee)

Estradiol Vaginal Ring vs. Oral Oxybutynin for Overactive Bladder

Topics

Reviewing Author